Results - Financial results for the quarter and half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.3 pts less than Nifty Microcap 250 and 5.9 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medico Intercontinental Ltd reported unaudited standalone and consolidated results for Q2 FY26 and H1 FY26 ended September 30, 2025, approved at the board meeting on November 14, 2025. Standalone revenue from operations came in at Rs 1,241.95 lakhs for Q2, down about 7.8% from Rs 1,346.53 lakhs in Q2 FY25, while H1 revenue grew roughly 4% to Rs 2,695.73 lakhs. Standalone net profit fell sharply — about 40% YoY to Rs 59.19 lakhs in Q2 and roughly 23% to Rs 114.80 lakhs in H1 — hurt by higher other expenses and finance costs. Standalone EPS for Q2 dropped to Rs 0.59 from Rs 0.97. The statutory auditor V. Goswami & Co issued an unmodified limited-review opinion on both standalone and consolidated results. The company also disclosed a change in accounting policy for its joint venture (Medico Lab), moving from proportionate consolidation to the equity method under Ind AS 28, leading to retrospective restatement of prior-period consolidated figures.
Short-term sentiment may be weak given the sharp drop in Q2 standalone profits, although H1 revenue was modestly higher year-on-year; restated comparatives due to the JV accounting change make like-for-like analysis less straightforward for investors.